CLVS Key Statistics, Chart & Performance
The current stock price of CLVS is 0.0812 USD. In the past month the price decreased by -76.84%. In the past year, price decreased by -97.44%.
CLVS Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.31 | 406.04B | ||
| AMGN | AMGEN INC | 15.03 | 176.99B | ||
| GILD | GILEAD SCIENCES INC | 15.04 | 152.83B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.14 | 115.12B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.19 | 81.34B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 778.92 | 52.48B | ||
| INSM | INSMED INC | N/A | 37.13B | ||
| NTRA | NATERA INC | N/A | 31.74B | ||
| BIIB | BIOGEN INC | 10.54 | 25.88B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.8 | 21.37B | ||
| INCY | INCYTE CORP | 15.41 | 19.42B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.34B |
Related stock screener links
About CLVS
Company Profile
Clovis Oncology, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of innovative anti-cancer agents in the United States, Europe, and additional international markets. The company is headquartered in Boulder, Colorado and currently employs 413 full-time employees. The company went IPO on 2011-11-16. The firm is focused on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and additional international markets. Its segments include U.S. and ex-U.S. Its product, Rubraca, is an oral small molecule inhibitor of poly ADP-ribose polymerase (PARP) marketed in the United States for two indications specific to recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer and an indication specific to metastatic castration-resistant prostate cancer (mCRPC). Its FAP-2286, is an investigational diagnostic and therapeutic agent targeting fibroblast activation protein (FAP). The company also provides Lucitanib, which is an investigational, oral, potent angiogenesis inhibitor, which inhibits vascular endothelial growth factor receptors 1 through 3 (VEGFR1-3), platelet-derived growth factor receptors alpha and beta (PDGFR α/β) and fibroblast growth factor receptors 1 through 3 (FGFR1-3).
Company Info
CLOVIS ONCOLOGY INC
Suite 100, 2525 28Th Street
Boulder COLORADO 80301 US
CEO: Patrick J. Mahaffy
Employees: 413
Phone: 13036255000.0
CLOVIS ONCOLOGY INC / CLVS FAQ
Can you describe the business of CLOVIS ONCOLOGY INC?
Clovis Oncology, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of innovative anti-cancer agents in the United States, Europe, and additional international markets. The company is headquartered in Boulder, Colorado and currently employs 413 full-time employees. The company went IPO on 2011-11-16. The firm is focused on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and additional international markets. Its segments include U.S. and ex-U.S. Its product, Rubraca, is an oral small molecule inhibitor of poly ADP-ribose polymerase (PARP) marketed in the United States for two indications specific to recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer and an indication specific to metastatic castration-resistant prostate cancer (mCRPC). Its FAP-2286, is an investigational diagnostic and therapeutic agent targeting fibroblast activation protein (FAP). The company also provides Lucitanib, which is an investigational, oral, potent angiogenesis inhibitor, which inhibits vascular endothelial growth factor receptors 1 through 3 (VEGFR1-3), platelet-derived growth factor receptors alpha and beta (PDGFR α/β) and fibroblast growth factor receptors 1 through 3 (FGFR1-3).
What is the current price of CLVS stock?
The current stock price of CLVS is 0.0812 USD. The price decreased by -5.58% in the last trading session.
Does CLOVIS ONCOLOGY INC pay dividends?
CLVS does not pay a dividend.
How is the ChartMill rating for CLOVIS ONCOLOGY INC?
CLVS has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
What is the analyst forecast for CLVS stock?
7 analysts have analysed CLVS and the average price target is 2.04 USD. This implies a price increase of 2412.32% is expected in the next year compared to the current price of 0.0812.
CLVS Technical Analysis
CLVS Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to CLVS. CLVS may be in some trouble as it scores bad on both profitability and health.
CLVS Financial Highlights
Over the last trailing twelve months CLVS reported a non-GAAP Earnings per Share(EPS) of -1.81. The EPS increased by 36.04% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
CLVS Forecast & Estimates
7 analysts have analysed CLVS and the average price target is 2.04 USD. This implies a price increase of 2412.32% is expected in the next year compared to the current price of 0.0812.
For the next year, analysts expect an EPS growth of 28.29% and a revenue growth -14% for CLVS